Fruquin 5 mg Tablet (Fruquintinib) | Metastatic Colorectal Cancer Therapy

Fruquin 5 mg is a highly selective, oral kinase inhibitor containing the active molecule Fruquintinib. It is specifically formulated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have exhausted standard therapeutic options. By potently blocking Vascular Endothelial Growth Factor Receptors (VEGFR) 1, 2, and 3, Fruquintinib actively disrupts tumor angiogenesis—the process by which cancer cells generate new blood vessels to survive and metastasize. As a clinically bioequivalent alternative to the innovator brand Fruzaqla, Fruquin provides a critical, evidence-based intervention for advanced oncology protocols.

Expert Insight By Medical Reviewer

“Managing heavily pre-treated metastatic colorectal cancer requires treatments that balance disease control with manageable toxicity. Dr. Salma Elreedy emphasizes that Fruquintinib’s high selectivity for VEGFR-1, -2, and -3 is its primary clinical advantage. Because it precisely targets the angiogenesis pathway while minimizing off-target kinase inhibition, it offers a predictable safety profile. This allows oncology teams to maintain dose intensity and preserve the patient’s quality of life during late-line therapy.“

Clinical Data: Mechanism, Dosing, and Efficacy

Who is the exact candidate for this medication?

Fruquin is indicated for adult patients with metastatic colorectal cancer (mCRC) who have experienced disease progression following prior standard therapies. Specifically, candidates must have previously been treated with (according to the FDA approval):

• Fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy regimens.
• An anti-VEGF biological therapy (e.g., bevacizumab).
• An anti-EGFR therapy (e.g., cetuximab or panitumumab), strictly if their tumor is RAS wild-type.

How does Fruquintinib work at a molecular level?

Tumors rely on a dedicated blood supply to grow beyond a few millimeters. They achieve this by secreting VEGF, a signaling protein that binds to receptors (VEGFR) on nearby blood vessels, stimulating new vessel growth. Fruquintinib is a small molecule inhibitor that selectively binds to the intracellular kinase domain of VEGFR-1, -2, and -3. By blocking the ATP-binding site of these receptors, it halts the downstream signaling cascade (including the MAPK and PI3K/AKT pathways related to endothelial cell proliferation). This effectively “starves” the tumor of oxygen and nutrients.

What are the standard dosage and administration protocols?

The recommended clinical dose is 5 mg taken orally once daily for the first 21 days of each 28-day treatment cycle.

• Administration: Tablets should be swallowed whole with water. It can be taken with or without food, but should be taken at approximately the same time each day to maintain steady-state pharmacokinetics.
• Missed Doses: If a patient misses a dose, they should take it as soon as they remember on the same day. If it is the next day, skip the missed dose and resume the regular schedule. Do not take two doses on the same day to make up for a missed tablet.

What is the expected safety profile and how are adverse events managed?

Fruquintinib is generally well-tolerated, but routine monitoring is required.

• Very Common (>20%): Hypertension, dysphonia (hoarseness), palmar-plantar erythrodysesthesia (hand-foot syndrome), and fatigue.
• Adverse Event Reporting Warning: Severe hypertension and hemorrhagic events have been documented. Blood pressure must be monitored weekly for the first month and at least monthly thereafter.
• Actionable Advice for Hand-Foot Syndrome: Patients should be advised to apply thick, alcohol-free moisturizing creams containing urea to the hands and feet daily, wear thick cotton socks, and avoid hot water or heavy friction on the extremities during the first cycle.

What is the clinical trial evidence supporting its use?

The efficacy of Fruquintinib is heavily grounded in the global Phase III FRESCO-2 trial (NCT04322539), published in The Lancet. The trial evaluated heavily pre-treated mCRC patients. The data demonstrated a statistically significant improvement in Overall Survival (OS). Patients receiving fruquintinib achieved a median OS of 7.4 months compared to 4.8 months in the placebo group, alongside significant improvements in Progression-Free Survival (PFS), firmly establishing its role in late-line mCRC management.

Precautions & Special Populations

• Pregnancy & Lactation: Fruquintinib can cause fetal harm based on its mechanism of action. Females of reproductive potential must use highly effective contraception during treatment and for at least 2 weeks after the final dose. Lactating women should not breastfeed during this period.
• Hepatic Impairment: No dose adjustment is recommended for patients with mild hepatic impairment. It has not been adequately studied in severe hepatic impairment; use with extreme caution and clinical monitoring.
• Storage and Logistics: Fruquin 5 mg does not require cold-chain logistics. Store at controlled room temperature between 20°C and 25°C (68°F to 77°F). Keep in the original container to protect from moisture.

Manufacturer Trust & Global Access

Manufacturer Quality Assurance

Fruquin is manufactured by Everest Pharmaceutical, a specialized oncology producer. To ensure patient safety and therapeutic efficacy, Everest operates strictly under WHO-GMP (World Health Organization Good Manufacturing Practices) guidelines. Every batch undergoes rigorous molecular purity testing and clinical bioequivalence assessments to ensure it matches the pharmacological profile of the innovator brand, Fruzaqla.

Navigating Global Access and Importation

For patients located in jurisdictions where Fruquin 5 mg is not yet commercially registered or stocked locally, access is still legally permissible through established medical channels. Under “Named Patient” or “Personal Use Importation” regulations, patients can import life-saving oncology medications directly from verified, licensed exporters. This process strictly requires a valid prescription and medical summary from the patient’s treating oncologist. This ensures that the acquisition of Fruquin complies with international medical distribution laws and that the patient remains under the direct supervision of their healthcare provider.

Frequently Asked Questions (FAQs)